:: Volume 8, Issue 1 (1-2017) ::
Caspian J Intern Med 2017, 8(1): 35-43 Back to browse issues page
Effect of SeptimebTM as a new natural extract on severe sepsis: A randomized clinical trial
Alieh Pourdast , Maryam Sanaie , Sirous Jafari , Mostafa Mohammadi , Hossein Khalili , Gita Shafiee , Zeinab Ahadi , Mahsa Rostami , Saba Alizad , Ramin Heshmat , Minoo Mohraz
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran , ahadi.ze@gmail.com
Abstract:   (8709 Views)

Background: Septimeb as a herbal medicine has regulatory effects on inflammation. This study set to evaluate the effects of Septimeb among patients with sepsis on inflammatory biomarkers and survival rate.

Methods: In this randomized clinical trial, 51 patients with sepsis from the ICU and medical ward of Imam Khomeini Hospital were divided into two groups: Septimeb (n=25) and control group (n=26). In the control group, the patients received a standard treatment only for 7 days, while Septimeb group received Septimeb (6cc vial with 500cc serum glucose infusion 5% daily for one to two hours) plus standard treatment of sepsis for 7 days. Then, blood samples were analyzed. APACHE (Acute Physiologic and Chronic Health Evaluation), SOFA (Sequential Organ Failure Assessment), and GCS (Glasgow Coma Score) values were calculated daily.

Results: Treatment with Septimeb showed a significant decrease in SOFA value (1.54±0.83) compared to the control group (2.39±0.88) (P<0.001) and a significant increase in GCS value (14.46±0.88) compared to the control group (12.86±1.78) (P<0.001).  Improvements of these values can confirm the potential of Septimeb in the reduction of severity of sepsis (P<0.05). There were significant decreases in lactate and blood sugar and WBC levels. In addition, inflammatory factors such as ESR (Septimeb group: 52.07±34.80, control group: 51.75±42.10, P=0.98) and CRP (Septimeb group: 48.86±23.21, control group: 49.93±36.22, P=0.92) decreased, but did not show a significant reduction.

Conclusion: Septimeb has positive effects on reduction of the severity of sepsis which leads to reduction of patients’ mortality rates.

Keywords: Sepsis, Septimeb, Infection, Inflammatory
Full-Text [PDF 514 kb]   (1808 Downloads)    
Type of Study: Original Article | Subject: Infectious Diseases
Received: 2016/05/8 | Accepted: 2016/09/5 | Published: 2016/11/15


XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 8, Issue 1 (1-2017) Back to browse issues page